You are here: Home / Cancer Research Network / Dr Georgina Long / Dr Georgina Long 

Dr Georgina Long

Cancer Institute NSW Fellow
Surgery, Central Clinical School
Sydney Melanoma Unit

T: +61 2 9845 8089.
E:
Curriculum vitae

Current national competitive grants*

2011

Manipulating the B-RAF/MEK pathway in the genesis and treatment of melanoma
Rizos H, Kefford R, Long G, Zhang X
National Health and Medical Research Council Project Grant ($543,390 over 3 years)

* Grants administered through the University of Sydney

Back to Top

Keywords

Molecular biology; Cancer; Melanoma and skin cancer

Back to Top

International links

United States. (M.D Anderson- Harvard) Epidemiological studies in Stage IV melenoma patients.

Back to Top

Publications

2013 | 2012 | 2011 | 2007

2013

   
  • Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013), BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer. 49(5), 1073-1079. [Abstract]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013), Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. American Journal of Surgical Pathology. 37(1), 61-65. [Abstract]
  • Carlino, M., Saunders, C., Haydu, L., Menzies, A., Martin Curtis, C., Lebowitz, P., Kefford, R., Long, G. (2013), (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer. 49(2), 395-402. [Abstract]

2012

   
Back to Top
  • Flaherty, K., Infante, J., Daud, A., Gonzalez, R., Kefford, R., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Kudchadkar, R., Burris, H., Falchook, G., Algazi, A., Lewis, K., Long, G., Puzanov, I., Lebowitz, P., Singh, A., Little, S., Sun, P., Allred, A., Ouellet, D., Kim, K., Patel, K., Weber, J. (2012), Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England journal of medicine. 367(18), 1694-1703. [Abstract]
  • Long, G., Trefzer, U., Davies, M., Kefford, R., Ascierto, P., Chapman, P., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., Mortier, L., Tawbi, H., Wilhelm, T., Zimmer, L., Switzky, J., Swann, S., Martin, A., Guckert, M., Goodman, V., Streit, M., Kirkwood, J., Schadendorf, D. (2012), Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. The Lancet Oncology. 13(11), 1087-1095. [Abstract]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012), Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Molecular Cancer Therapeutics. 11(12), 2704-2708. [Abstract]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012), Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology. 1(6), 997-999. [Abstract]
  • Anforth, R., Blumetti, T., Kefford, R., Sharma, R., Scolyer, R., Kossard, S., Long, G., Fernandez-Pe��as, P. (2012), Cutaneous Manifestations of Dabrafenib (GSK2118436): A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma. British Journal of Dermatology. 167(5), 1153-1160. [Abstract]
  • Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M., Busam, K., Carvajal, R., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S., Dummer, R., Long, G., McArthur, G., Scherag, A., Sucker, A., Schadendorf, D. (2012), Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology. 30(19), 2375-2383. [Abstract]
  • Murali, R., Brown, P., Kefford, R., Scolyer, R., Thompson, J., Atkins, M., Long, G. (2012), Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer. 118(18), 4519-4529. [Abstract]
  • Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012), Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research. 18(12), 3242-3249. [Abstract]
  • Murali, R., Haydu, L., Long, G., Quinn, M., Saw, R., Shannon, K., Spillane, A., Stretch, J., Kefford, R., Thompson, J., Scolyer, R. (2012), Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology. 19(6), 1782-1789. [Abstract]
  • Falchook, G., Long, G., Kurzrock, R., Kim, K., Arkenau, T., Brown, M., Hamid, O., Infante, J., Millward, M., Pavlick, A., O'Day, S., Blackman, S., Curtis, C., Lebowitz, P., Ma, B., Ouellet, D., Kefford, R. (2012), Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet. 379(9829), 1893-1901. [Abstract]
  • Shi, H., Moriceau, G., Kong, X., Koya, R., Nazarian, R., Pupo, G., Bacchiocchi, A., Dahlman, K., Chmielowski, B., Sosman, J., Halaban, R., Kefford, R., Long, G., Ribas, A., Lo, R. (2012), Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery. 2(5), 414-424. [Abstract]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012), Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma. Clinical Cancer Research. 18(5), 1386-1394. [Abstract]
  • Shi, H., Moriceau, G., Kong, X., Lee, M., Lee, H., Koya, R., Ng, C., Chodon, T., Scolyer, R., Dahlman, K., Sosman, J., Kefford, R., Long, G., Nelson, S., Ribas, A., Lo, R. (2012), Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications. 3(2), 724. [Abstract]
  • Menzies, A., Long, G., Murali, R. (2012), Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy. 6, 391-405. [Abstract]
  • Carlino, M., Fogarty, G., Long, G. (2012), Treatment of melanoma brain metastases: a new paradigm. Cancer Journal. 18(2), 208-212. [Abstract]

2011

   
Back to Top
  • Scolyer, R., Long, G., Thompson, J. (2011), Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular oncology. 5(2), 124-36. [Abstract]
  • Long, G., Menzies, A., Nagrial, A., Haydu, L., Hamilton, A., Mann, G., Hughes, T., Thompson, J., Scolyer, R., Kefford, R. (2011), Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. Journal of Clinical Oncology. 29(10), 1239-1246. [Abstract]
  • Arkenau, H., Kefford, R., Long, G. (2011), Targeting BRAF for patients with melanoma. British journal of cancer. 104(3), 392-8. [Abstract]

2007

   
Back to Top
  • Long, G., Tattersall, M. (2007), Lung encasement by metastatic osteoblastic sarcoma. The Medical journal of Australia. 186(2), 100-100. [Abstract]
  • Long, G. (2007), Book review: The Molecular Biology of Cancer. CancerForum. 31(2), 121.